Verastem’s KRAS Inhibitor Shows Strong Early Data in Pancreatic and Lung Cancer Trials
Verastem Oncology reported promising phase 1/2 results for VS-7375, an oral KRAS G12D inhibitor, showing high survival rates in pancreatic cancer and response rates in lung cancer. The company plans a phase 3 trial by year-end and seeks partnerships, following a strategic pivot from its underperforming ovarian cancer drugs.